257 related articles for article (PubMed ID: 25285595)
21. Multiple sclerosis pathways: an innovative nursing role in disease management.
Madonna MG; Keating MM
J Neurosci Nurs; 1999 Dec; 31(6):332-5. PubMed ID: 10726241
[TBL] [Abstract][Full Text] [Related]
22. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β.
Zecca C; Riccitelli GC; Calabrese P; Pravatà E; Candrian U; Guttmann CR; Gobbi C
BMC Neurol; 2014 Feb; 14():38. PubMed ID: 24576156
[TBL] [Abstract][Full Text] [Related]
23. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis.
Schwartz CE; Coulthard-Morris L; Cole B; Vollmer T
Arch Neurol; 1997 Dec; 54(12):1475-80. PubMed ID: 9400356
[TBL] [Abstract][Full Text] [Related]
24. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
25. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
[TBL] [Abstract][Full Text] [Related]
26. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
27. [Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain].
Piñol C
Neurologia; 2016 May; 31(4):247-54. PubMed ID: 25976942
[TBL] [Abstract][Full Text] [Related]
28. Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.
Qu ZX; Pliskin N; Jensen MW; White D; Arnason BG
Arch Neurol; 2001 Jan; 58(1):87-90. PubMed ID: 11176940
[TBL] [Abstract][Full Text] [Related]
29. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
[TBL] [Abstract][Full Text] [Related]
30. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
[TBL] [Abstract][Full Text] [Related]
31. Treatment with interferon beta-1b improves quality of life in multiple sclerosis.
Rice GP; Oger J; Duquette P; Francis GS; Bélanger M; Laplante S; Grenier JF
Can J Neurol Sci; 1999 Nov; 26(4):276-82. PubMed ID: 10563212
[TBL] [Abstract][Full Text] [Related]
32. Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis.
Marziniak M; Meuth S
Adv Ther; 2014 Sep; 31(9):915-31. PubMed ID: 25182864
[TBL] [Abstract][Full Text] [Related]
33. The impact of a patient support program for multiple sclerosis on patient satisfaction and subjective health status.
Kohlmann T; Wang C; Lipinski J; Hadker N; Caffrey E; Epstein M; Sadasivan R; Gondek K
J Neurosci Nurs; 2013 Jun; 45(3):E3-14. PubMed ID: 23636073
[TBL] [Abstract][Full Text] [Related]
34. Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction.
Zimmer A; Bläuer C; Coslovsky M; Kappos L; Derfuss T
Mult Scler Relat Disord; 2015 Sep; 4(5):444-450. PubMed ID: 26346793
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis.
Mokhber N; Azarpazhooh A; Orouji E; Khorram B; Modares Gharavi M; Kakhi S; Khallaghi H; Azarpazhooh MR
Psychiatry Clin Neurosci; 2015 Oct; 69(10):649-57. PubMed ID: 25907350
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
Zettl UK; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Limmroth V;
BMC Neurol; 2013 Sep; 13():117. PubMed ID: 24011220
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.
Saiz A; Mora S; Blanco J;
Neurologia; 2015 May; 30(4):214-22. PubMed ID: 24484756
[TBL] [Abstract][Full Text] [Related]
38. Caregiver burden, quality of life and walking ability in different disability levels of multiple sclerosis.
Ertekin Ö; Özakbaş S; İdiman E
NeuroRehabilitation; 2014; 34(2):313-21. PubMed ID: 24419020
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
[TBL] [Abstract][Full Text] [Related]
40. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.
Touchette DR; Durgin TL; Wanke LA; Goodkin DE
Clin Ther; 2003 Feb; 25(2):611-34. PubMed ID: 12749517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
